PDCD1 and head and neck squamous cell carcinoma: Cadonilimab a novel bispecific antibody that targets both PD-1 and CTLA-4, showed an 18.2% response rate in a phase 1b/2 study (NCT03852251), but its efficacy in HNSCC needs further validation [100].